Mike Ouimette - 09 Jul 2024 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role: General Counsel & Corp. Sec'y
Signature: /s/ Mike Ouimette, attorney-in-fact
Issuer symbol: PLRX
Transactions as of: 09 Jul 2024
Transactions value $: $0
Form type: 4
Filing time: 11 Jul 2024, 16:41:53 UTC
Previous filing: 24 Jan 2024
Next filing: 12 Jul 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLRX	Common Stock	Award	$0	+15K	+17.24%	$0.00	102K	09 Jul 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 28, 2022, the Reporting Person was granted 54,374 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 14,954 shares.

Content

On July 28, 2022, the Reporting Person was granted 54,374 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 14,954 shares.